Lumos Pharma (LUMO) Competitors $4.32 -0.01 (-0.23%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LUMO vs. EQ, ELUT, ATOS, DRUG, FTLF, NLTX, SGMT, ABOS, PBYI, and BDTXShould you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Equillium (EQ), Elutia (ELUT), Atossa Therapeutics (ATOS), Bright Minds Biosciences (DRUG), FitLife Brands (FTLF), Neoleukin Therapeutics (NLTX), Sagimet Biosciences (SGMT), Acumen Pharmaceuticals (ABOS), Puma Biotechnology (PBYI), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Lumos Pharma vs. Equillium Elutia Atossa Therapeutics Bright Minds Biosciences FitLife Brands Neoleukin Therapeutics Sagimet Biosciences Acumen Pharmaceuticals Puma Biotechnology Black Diamond Therapeutics Lumos Pharma (NASDAQ:LUMO) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability. Which has higher valuation and earnings, LUMO or EQ? Equillium has higher revenue and earnings than Lumos Pharma. Equillium is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLumos Pharma$2.05M18.23-$34.03M-$4.29-1.01Equillium$36.08M0.71-$13.34M-$0.14-5.13 Do insiders and institutionals hold more shares of LUMO or EQ? 34.0% of Lumos Pharma shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 25.4% of Lumos Pharma shares are held by insiders. Comparatively, 30.3% of Equillium shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor LUMO or EQ? In the previous week, Equillium had 6 more articles in the media than Lumos Pharma. MarketBeat recorded 6 mentions for Equillium and 0 mentions for Lumos Pharma. Equillium's average media sentiment score of 0.38 beat Lumos Pharma's score of 0.00 indicating that Equillium is being referred to more favorably in the news media. Company Overall Sentiment Lumos Pharma Neutral Equillium Neutral Does the MarketBeat Community favor LUMO or EQ? Lumos Pharma received 1 more outperform votes than Equillium when rated by MarketBeat users. However, 83.72% of users gave Equillium an outperform vote while only 75.51% of users gave Lumos Pharma an outperform vote. CompanyUnderperformOutperformLumos PharmaOutperform Votes3775.51% Underperform Votes1224.49% EquilliumOutperform Votes3683.72% Underperform Votes716.28% Is LUMO or EQ more profitable? Equillium has a net margin of -10.05% compared to Lumos Pharma's net margin of -1,583.49%. Equillium's return on equity of -20.68% beat Lumos Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lumos Pharma-1,583.49% -233.03% -129.88% Equillium -10.05%-20.68%-10.77% Do analysts prefer LUMO or EQ? Lumos Pharma presently has a consensus price target of $8.63, suggesting a potential upside of 99.65%. Equillium has a consensus price target of $5.00, suggesting a potential upside of 596.28%. Given Equillium's higher probable upside, analysts clearly believe Equillium is more favorable than Lumos Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumos Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, LUMO or EQ? Lumos Pharma has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. SummaryEquillium beats Lumos Pharma on 12 of the 17 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Lumos Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUMO vs. The Competition Export to ExcelMetricLumos PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.45M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.014.4283.5712.93Price / Sales18.23375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book7.5810.126.936.25Net Income-$34.03M$153.61M$119.12M$225.93M7 Day Performance-0.23%-2.00%-1.83%-1.32%1 Month Performance15.81%-7.47%-3.64%0.60%1 Year Performance41.64%31.80%31.64%26.23% Lumos Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUMOLumos Pharma3.2102 of 5 stars$4.32-0.2%$8.63+99.7%+41.2%$37.37M$2.05M-1.0130EQEquillium3.1992 of 5 stars$0.71-1.4%$5.00+605.8%+43.6%$25.10M$36.08M0.0040Analyst RevisionELUTElutia2.685 of 5 stars$4.38+4.0%$10.00+128.3%+170.4%$149.18M$24.75M0.00180ATOSAtossa Therapeutics1.2137 of 5 stars$1.18-1.7%$6.75+472.0%+62.2%$148.44MN/A-5.458Analyst DowngradeAnalyst RevisionDRUGBright Minds Biosciences0.8622 of 5 stars$33.25+1.8%N/A+2,513.4%$147.30MN/A0.00N/AFTLFFitLife Brands4.0645 of 5 stars$31.83+2.3%$40.00+25.7%+59.9%$146.42M$52.70M18.8320Analyst RevisionNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeSGMTSagimet Biosciences2.1861 of 5 stars$4.65+2.9%$21.60+364.5%+50.2%$142.62M$2M0.008ABOSAcumen Pharmaceuticals2.6635 of 5 stars$2.37-0.8%$9.00+279.7%+0.4%$142.39MN/A0.0051Analyst RevisionPBYIPuma Biotechnology4.4141 of 5 stars$2.89+1.8%$7.00+142.2%-27.0%$141.87M$235.60M5.92185Analyst ForecastPositive NewsBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.49+2.5%$15.50+522.5%+8.0%$140.88MN/A0.0090Positive News Related Companies and Tools Related Companies Equillium Competitors Elutia Competitors Atossa Therapeutics Competitors Bright Minds Biosciences Competitors FitLife Brands Competitors Neoleukin Therapeutics Competitors Sagimet Biosciences Competitors Acumen Pharmaceuticals Competitors Puma Biotechnology Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LUMO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
